AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
chlorphentermine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anorexics | 618 | 461-78-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A sympathomimetic agent that was formerly used as an anorectic. It has properties similar to those of DEXTROAMPHETAMINE. It has been implicated in lipid storage disorders and pulmonary hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1223)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 0 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 17 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.87 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK | 48 | |||
| kinase-selectivity-class | AKT1,AKT2,AKT3,AXL,EIF2AK3,GRK2,PDK4,PRKACA,PRKCD | 9 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | PARKE DAVIS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D013566 | Sympathomimetics |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Obesity | indication | 414916001 | DOID:9970 |
| Heart valve disorder | contraindication | 368009 | DOID:4079 |
| Alcoholism | contraindication | 7200002 | |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Feeling agitated | contraindication | 24199005 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Mild pre-eclampsia | contraindication | 41114007 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Substance abuse | contraindication | 66214007 | |
| Psychotic disorder | contraindication | 69322001 | |
| Pulmonary hypertension | contraindication | 70995007 | DOID:6432 |
| Secondary glaucoma | contraindication | 95717004 | |
| Angina pectoris | contraindication | 194828000 | |
| Edema | contraindication | 267038008 | |
| Syncope | contraindication | 271594007 | |
| Arteriosclerosis obliterans | contraindication | 361133006 | DOID:5160 |
| Hypertensive urgency | contraindication | 443482000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.92 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium-dependent serotonin transporter | Transporter | SUBSTRATE | Ki | 6.47 | WOMBAT-PK | CHEMBL | |||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.40 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| D03476 | KEGG_DRUG |
| 151-06-4 | SECONDARY_CAS_RN |
| 220218 | RXNORM |
| C0008283 | UMLSCUI |
| CHEBI:3646 | CHEBI |
| CHEMBL1201269 | ChEMBL_ID |
| DB01556 | DRUGBANK_ID |
| CHEMBL1200595 | ChEMBL_ID |
| D002745 | MESH_DESCRIPTOR_UI |
| 10007 | PUBCHEM_CID |
| 1055 | INN_ID |
| NHW07912O7 | UNII |
| 13941 | MMSL |
| 001872 | NDDF |
| 004775 | NDDF |
| 9643009 | SNOMEDCT_US |
| NHW07912O7 | INXIGHT DRUGS |
Pharmaceutical products:
None